Compare · MDT vs PTHL
MDT vs PTHL
Side-by-side comparison of Medtronic plc. (MDT) and Pheton Holdings Ltd (PTHL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and PTHL operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT carries a market cap of $103.60B.
- Over the past year, MDT is down 7.8% and PTHL is down 94.1% - MDT leads by 86.3 points.
- MDT has hit the wire 21 times in the past 4 weeks while PTHL has been quiet.
- MDT has more recent analyst coverage (25 ratings vs 0 for PTHL).
- Company
- Medtronic plc.
- Pheton Holdings Ltd
- Price
- $80.66-1.20%
- $0.89+108.26%
- Market cap
- $103.60B
- -
- 1M return
- +3.49%
- +58.91%
- 1Y return
- -7.80%
- -94.06%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 21
- 0
- Recent ratings
- 25
- 0
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest MDT
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 6,817 units of Ordinary Shares, decreasing direct ownership by 14% to 41,416 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey covered exercise/tax liability with 41,936 units of Ordinary Shares, decreasing direct ownership by 12% to 301,163 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 7,471 units of Ordinary Shares, decreasing direct ownership by 11% to 63,122 units (SEC Form 4)
- SVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 2,840 units of Ordinary Shares, decreasing direct ownership by 7% to 38,689 units (SEC Form 4)
- Chief Accounting Officer Blomquist Denise L. covered exercise/tax liability with 237 units of Ordinary Shares, decreasing direct ownership by 2% to 14,737 units (SEC Form 4)
- Medtronic upgraded by BTIG Research with a new price target
- Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
- Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens
- Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
Latest PTHL
- SEC Form 6-K filed by Pheton Holdings Ltd
- Pheton Holdings Ltd Announces Corporate Name Change and Stock Ticker Symbol Change
- SEC Form 6-K filed by Pheton Holdings Ltd
- SEC Form 6-K filed by Pheton Holdings Ltd
- SEC Form 6-K filed by Pheton Holdings Ltd
- SEC Form 6-K filed by Pheton Holdings Ltd
- Pheton Holdings Ltd Announces Closing of Share Acquisition with iTonic Corporation
- SEC Form 6-K filed by Pheton Holdings Ltd
- SEC Form 6-K filed by Pheton Holdings Ltd
- SEC Form 6-K filed by Pheton Holdings Ltd